Vitamin D analogues: How do they differ and what is their clinical role?

Nephrology Dialysis Transplantation

Volumn 16, Issue 10, 2001, Pages 1965-1967

  Steddon, Simon J ^a   Schroeder, Neil J ^a   Cunningham, John ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; DIHYDROTACHYSTEROL; DOXERCALCIFEROL; FALECALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; PRODRUG; RETINOID X RECEPTOR; VITAMIN D BINDING PROTEIN; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; BONE DISEASE; CATTLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG SYNTHESIS; EDITORIAL; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MULTICENTER STUDY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; UREMIA;

EID: 0034786319     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.10.1965     Document Type: Editorial

References (25)

1. Vitamin D analogues
2. The vitamin D hormone and its nuclear receptor: Molecular actions and disease states
3. 3
4. 3 receptor to positive and negative vitamin D response elements
5. 3
6. Vitamin D
7. Pathogenesis of secondary hyperparathyroidism
8. What is the optimal regimen for vitamin D?
9. Pathogenesis and histology of renal osteodystrophy
10. 3: Past, present and future
11. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion
12. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine
13. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia
14. 2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content
15. 2 on calcium and phosphorus resorption in bone
16. 2 decreases with duration of treatment
17. 2, calcitriol, and calcipotriol
18. Effects of new analogues of vitamin D on bone cells: Implications for treatment of uremic bone disease
19. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis
20. Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study
21. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism
22. 2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis
23. 2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism
24. 2) therapy for secondary hyperparathyroidism
25. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in haemodialysis patients with secondary hyperparathyroidism